Jump to main content
Jump to site search


EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer

Abstract

Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added as an adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticle showed targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticle exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy.

Back to tab navigation

Supplementary files

Publication details

The article was accepted on 19 Jul 2018 and first published on 07 Aug 2018


Article type: Paper
DOI: 10.1039/C8NR05803B
Citation: Nanoscale, 2018, Accepted Manuscript
  •   Request permissions

    EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer

    Y. li, Y. Du, X. liang, T. sun, H. Xue, J. Tian and Z. jin, Nanoscale, 2018, Accepted Manuscript , DOI: 10.1039/C8NR05803B

Search articles by author

Spotlight

Advertisements